<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212562</url>
  </required_header>
  <id_info>
    <org_study_id>75090409</org_study_id>
    <nct_id>NCT01212562</nct_id>
  </id_info>
  <brief_title>Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery</brief_title>
  <acronym>IMCX</acronym>
  <official_title>Open Label, Phase 3 Study of the Efficacy of Combination of Imiquimod and Cryosurgery in the Treatment of Primary Basal Cell Carcinomas of the Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ioannina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ioannina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of cryosurgery during continuing
      imiquimod application in the treatment of basal cell carcinoma of the skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of efficacy:

        -  Number of patient: N=50

        -  Inclusion criteria: Basal cell carcinoma of the skin proven with biopsy

        -  Exclusion criteria: (1) Size of the tumors &gt;2cm; (2) Distance from the eyelid &lt;1cm;
           (3)Number of tumors &gt;5

      Treatment protocol: Patients will apply imiquimod daily for 14 days on the tumor and a rim of
      2mm around the tumor. On day 14 a session of mild cryosurgery (2 cycles of 10-15 seconds,
      with open spray liquid nitrogen) will be applied and the patients will continue application
      of imiquimod for another 3 weeks before being evaluated again. Persisting erosion will be
      considered as persistence of the tumor and imiquimod will be continued for another 3 weeks
      with/or without a cryosurgery session. The patients will be evaluated at 1,3,6,12 months
      after discontinuation of imiquimod and yearly thereafter for relapse. In case of clinical
      relapse, it will be confirmed by biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of immunocryosurgery in the treatment of basal cell carcinoma of the skin</measure>
    <time_frame>1 months</time_frame>
    <description>Basal cell carcinomas of the skin will be treated with immunocryosurgery and the efficacy will be measured 1, 3, 6, and 12 months. Reappearance of the tumor within the primary lesion and 1cm around it will be considered as relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Tolerability of Immunocryosurgery</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Immunocryosurgery</arm_group_label>
    <description>2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunocryosurgery</intervention_name>
    <description>Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin</description>
    <arm_group_label>Immunocryosurgery</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples with anticoagulant at -20C
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with basal cell carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Basal cell carcinoma of the skin

          -  Size &lt; or = 2cm

          -  Number of tumors &lt; or = 5

          -  Distance from eyelids, mouth &gt;1cm

        Exclusion Criteria:

          -  Size &gt;2cm Number of tumors &gt; 5 Distance from eyelids or mouth &lt; or = 1cm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis D Bassukas, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical School, University of Ioannina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department for Skin and Venereal Diseases, University Hospital</name>
      <address>
        <city>Ioannina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Bassukas ID, Gaitanis G. Combination of cryosurgery and topical imiquimod: does timing matter for successful immunocryosurgery? Cryobiology. 2009 Aug;59(1):116-7. doi: 10.1016/j.cryobiol.2009.04.011. Epub 2009 May 6.</citation>
    <PMID>19426725</PMID>
  </reference>
  <reference>
    <citation>Bassukas ID, Gamvroulia C, Zioga A, Nomikos K, Fotika C. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Int J Dermatol. 2008 May;47(5):519-21. doi: 10.1111/j.1365-4632.2008.03562.x.</citation>
    <PMID>18412875</PMID>
  </reference>
  <reference>
    <citation>Gaitanis G, Mitsou G, Tsiouri G, Alexis I, Bassukas ID. Cryosurgery during imiquimod cream treatment (&quot;immunocryosurgery&quot;) for Bowen's disease of the skin: a case series. Acta Derm Venereol. 2010 Sep;90(5):533-4. doi: 10.2340/00015555-0896.</citation>
    <PMID>20814639</PMID>
  </reference>
  <results_reference>
    <citation>Gaitanis G, Nomikos K, Vava E, Alexopoulos EC, Bassukas ID. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1427-31. doi: 10.1111/j.1468-3083.2009.03224.x. Epub 2009 Jun 25.</citation>
    <PMID>19555364</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ioannina</investigator_affiliation>
    <investigator_full_name>Ioannis Bassukas</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>basal cell carcinoma</keyword>
  <keyword>cryosurgery</keyword>
  <keyword>imiquimod</keyword>
  <keyword>immunocryosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

